AnaptysBio (NASDAQ: ANAB) grants options, RSUs to director Ware

Rhea-AI Filing Summary

AnaptysBio, Inc. granted equity awards to director Ware J. Anthony. On 01/06/2026, he received a stock option for 5,500 shares of common stock with a $43.91 exercise price and no upfront cost. The option vests in 12 equal monthly installments of 1/12 each, starting on February 6, 2026, as long as he continues providing service to the company on each vesting date.

On the same date, he was also granted 4,000 restricted stock units. Each RSU represents a right to receive one share of AnaptysBio common stock for no consideration. All 4,000 RSUs are scheduled to vest in full on the date of AnaptysBio’s 2027 annual meeting of shareholders, subject to his continued service through that date.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ware J. Anthony

(Last) (First) (Middle)

C/O ANAPTYSBIO, INC.

10770 WATERIDGE CIRCLE, SUITE 210

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ANAPTYSBIO, INC [ ANAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$43.91	01/06/2026		A		5,500		(1)	01/05/2036	Common Stock	5,500	$0	5,500	D
Restricted Stock Unit	(2)	01/06/2026		A		4,000		(3)	(3)	Common Stock	4,000	$0	4,000	D

Explanation of Responses:

1. The stock option vests as to 1/12 of the total shares monthly commencing on Februray 6, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

2. Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.

3. The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

	/s/ Eric Loumeau, Attorney-in-Fact	01/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity awards did AnaptysBio (ANAB) grant to director Ware J. Anthony?

AnaptysBio granted 5,500 stock options with a $43.91 exercise price and 4,000 restricted stock units (RSUs) to director Ware J. Anthony on 01/06/2026.

How do the stock options granted to Ware J. Anthony by AnaptysBio vest?

The 5,500 stock options vest as to 1/12 of the total shares monthly, beginning on February 6, 2026, until fully vested, conditioned on his continued service on each vesting date.

What are the key terms of the RSU grant to AnaptysBio director Ware J. Anthony?

The grant consists of 4,000 RSUs. Each RSU converts into one share of common stock for no consideration, and 100% of the RSUs vest on the date of AnaptysBio’s 2027 annual meeting of shareholders, subject to continued service.

Is the equity awarded to Ware J. Anthony held directly or indirectly?

Both the 5,500 stock options and the 4,000 RSUs are reported as held with direct (D) ownership, with no indirect ownership entity disclosed.

What is Ware J. Anthony’s role at AnaptysBio (ANAB) in this Form 4?

Ware J. Anthony is reported as a director of AnaptysBio, Inc. in this Form 4, and the filing is made by one reporting person.